NASDAQ | VICL: 2.16  +0.01
investors
Investors

News Releases

DateSubject
December 29, 2009 Vical Confirms Advantages of DNA Technology Platform With Vaccine for H1N1 Influenza
December 28, 2009 Vical's Allovectin-7® Phase 3 Trial Receives Positive Review From Safety Monitoring Board
December 22, 2009 Vical and the University of Washington Receive U.S. Patent for Herpes Simplex DNA Vaccine
December 9, 2009 Vical Advocates DNA Vaccine Approach With Pandemic Influenza Experts
November 23, 2009 Vical Completes Final Patient Follow-Up in TransVax™ CMV Vaccine Phase 2 Trial
November 16, 2009 Vical Added to NASDAQ Biotechnology Index
November 10, 2009 Vical's DNA Vaccine Technology Addresses Challenges of Emerging Diseases
November 4, 2009 Vical Reports Third Quarter 2009 Financial Results and Progress in Key Development Programs
October 28, 2009 Vical Announces News Release and Conference Call Schedule for Third Quarter 2009 Financial Results
October 27, 2009 Vical to Present at BIOCOM Investor Conference
October 26, 2009 Vical's Vaxfectin® Adjuvant Drives 200-Fold Increase in Antibody Responses With Sanofi-Pasteur Fluzone® Seasonal Influenza Vaccine
October 7, 2009 Vical's TransVax™ CMV Vaccine Elicits Long-Term Immune Responses in Phase 2 Trial
October 1, 2009 U.S. Navy to Fund Vical's H1N1 Pandemic Influenza (Swine Flu) Vaccine
September 28, 2009 Vical Licensee Sanofi-aventis Completes Enrollment in Phase 3 Angiogenesis Trial
September 24, 2009 Vical Presents Positive Preclinical Results with Vaxfectin®-Formulated, Peptide-based Cancer Vaccine
September 14, 2009 Detailed Data From Vical's TransVax™ CMV Vaccine Phase 2 Trial Presented in Late-Breaker Session at ICAAC
September 10, 2009 Vical Pandemic Influenza Vaccine Demonstrates Cross-reactivity Against California, Texas and Mexico H1N1 Strains
September 8, 2009 Vical Receives $2.5 Million Payment for Funding of Allovectin-7® Phase 3 Trial
September 3, 2009 Vical Receives Broad U.S. Patent for Vaxfectin(R)-Formulated DNA Vaccines for Influenza; Coverage Includes All Seasonal and Pandemic Strains
September 2, 2009 Vical to Present At Upcoming Investor Conferences
August 6, 2009 Vical Reports Second Quarter 2009 Financial Results and Updates Progress in Key Programs
August 3, 2009 Vical and Teva Establish Sales and Marketing Agreement for Allovectin-7® in Israel
July 30, 2009 Vical Announces News Release and Conference Call Schedule For Second Quarter 2009 Financial Results
July 28, 2009 Federated Kaufmann Funds to Invest $10 Million in Vical
July 8, 2009 Vical TransVax™ CMV Vaccine Achieves Promising Interim Clinical Results in Phase 2 Trial
July 7, 2009 Vical Announces News Release and Conference Call/Webcast Schedule to Present TransVax™ CMV Vaccine Phase 2 Interim Efficacy Results
June 30, 2009 Vical H1 Influenza Vaccine Delivers Robust Preclinical Results With 100% Response
June 22, 2009 Vical Receives Milestone Payment From Merck & Co., Inc.
June 18, 2009 Vical Advances RapidResponse™ DNA Vaccine Platform Under $6 Million Grant From NIH
June 3, 2009 Vical Announces Issuance of U.S. Patent for Universal Influenza Vaccine Approach
June 1, 2009 Vical to Present At Upcoming Investor Conferences
May 27, 2009 Vical to Present Update On Pandemic Influenza Vaccine Program and Overview of Pivotal Phase 3 Melanoma Trial At ASGT Conference
May 26, 2009 Vical Receives Additional Commitment in Registered Direct Offering
May 22, 2009 Vical to Raise $15.4 Million in Registered Direct Offering
May 21, 2009 Vical Advances H1N1 Pandemic Influenza (Swine Flu) Vaccine
May 20, 2009 Vical to Open NASDAQ Stock Market
May 18, 2009 Vical Receives $2.5 Million Payment for Continued Funding of Allovectin-7® Phase 3 Trial
May 14, 2009 Vical Grants Johns Hopkins Bloomberg School of Public Health Academic License for Core Technology
May 7, 2009 Vical Reports First Quarter 2009 Financial Results and Progress in Key Programs
May 6, 2009 Vical and U.S. Navy to Expedite Development of H1N1 Pandemic Influenza (Swine Flu) Vaccine
April 30, 2009 Vical Announces News Release and Conference Call Schedule for First Quarter 2009 Financial Results
April 28, 2009 Vical Updates Lead Vaccine Programs At NFID Vaccine Research Conference and Addresses Potential Response to H1N1 Swine Influenza Outbreak
April 23, 2009 Vical Reports Publication of Key Research Findings for Immunotherapeutic Herpes Vaccine
April 9, 2009 Vical's Vaxfectin® Adjuvant Named One of 100 Great Investigational Drugs in Eighth Annual Ranking by Editors of R&D Directions
March 24, 2009 Vical's Allovectin-7® Phase 3 Trial Receives Positive Review From Safety Monitoring Board
March 5, 2009 Vical to Present At Upcoming Investor Conferences
February 17, 2009 Vical Reports 2008 Financial Results and Progress in Product Development Programs
February 13, 2009 Vical Presents Pandemic Influenza Vaccine Results and Outlook At WHO Meeting
February 11, 2009 Vical Receives $2.3 Million Payment for Continued Funding of Allovectin-7® Phase 3 Trial
February 10, 2009 Vical Announces News Release and Conference Call Schedule for 2008 Financial Results
January 14, 2009 Vical Announces Issuance of U.S. Patent No. 7,470,675 for Composition, Delivery and Use of Gene-Based Interferon-Omega

AnGes Ebola Antibody Therapy

P. 858 646 1100 10390 Pacific Center Court, San Diego, California 92121
Designed by Mentus
This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.